Is Evercore’s (EVR) New Healthcare Hire a Clue to Its Advisory-Led Growth Priorities?
- Earlier this month, Evercore announced that Eric Rabinowitz, a senior healthcare dealmaker with more than 20 years of experience and prior leadership roles at J.P. Morgan, Barclays, and Perrigo, has joined as a senior managing director in its healthcare investment banking group in New York.
- His appointment strengthens Evercore’s specialist bench in healthcare M&A, potentially reinforcing the firm’s efforts to grow fee-based advisory work in a complex, high-activity sector.
- We’ll now examine how bringing in an experienced healthcare M&A leader like Rabinowitz could influence Evercore’s broader investment narrative and growth outlook.
Invest in the nuclear renaissance through our list of 90 elite nuclear energy infrastructure plays powering the global AI revolution.
Evercore Investment Narrative Recap
To own Evercore, you need to believe its advisory franchise can keep turning complex deal activity into resilient, high quality earnings, while managing rising cost pressures and heavy reliance on M&A cycles. The key near term catalyst remains how consistently the deal pipeline converts into fees, and the biggest risk is that elevated compensation and non compensation costs pressure margins if activity cools. Rabinowitz’s hire supports sector depth but does not materially change those near term drivers.
The recent increase in the quarterly dividend to US$0.89 per share is the most relevant backdrop for Rabinowitz’s arrival. It underlines Evercore’s confidence in returning capital even as it keeps investing in senior talent and new offices. For investors, the tension between rewarding shareholders today and carrying higher fixed costs for future growth sits at the heart of the current catalyst and risk discussion around the stock.
Read the full narrative on Evercore (it's free!)
Evercore's narrative projects $5.2 billion revenue and $778.4 million earnings by 2029. This requires 4.8% yearly revenue growth and a $31.4 million earnings increase from $747.0 million today.
Uncover how Evercore's forecasts yield a $383.60 fair value, a 12% upside to its current price.
Exploring Other Perspectives
Yet while consensus sees steadier growth, the lowest analysts were assuming revenues of about US$4.1 billion and earnings of roughly US$555 million by 2029, which is information investors should be aware of...
Explore 3 other fair value estimates on Evercore - why the stock might be worth as much as 27% more than the current price!
Reach Your Own Conclusion
Disagree with existing narratives? Extraordinary investment returns rarely come from following the herd, so go with your instincts.
- A great starting point for your Evercore research is our analysis highlighting 2 key rewards and 1 important warning sign that could impact your investment decision.
- Our free Evercore research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate Evercore's overall financial health at a glance.
Seeking Other Investments?
The market won't wait. These fast-moving stocks are hot now. Grab the list before they run:
- Rare earth metals are an input to most high-tech devices, military and defence systems and electric vehicles. The global race is on to secure supply of these critical minerals. Beat the pack to uncover the 29 best rare earth metal stocks of the very few that mine this essential strategic resource.
- Capitalize on the AI infrastructure supercycle with our selection of the 53 best 'picks and shovels' of the AI gold rush converting record-breaking demand into massive cash flow.
- Explore 26 top quantum computing companies leading the revolution in next-gen technology and shaping the future with breakthroughs in quantum algorithms, superconducting qubits, and cutting-edge research.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com